Delivery Order 36F79724D0101-36C24925F0120
This federal contract award is for the delivery of BREYANZI, a chimeric antigen receptor (CAR) T cell immunotherapy product, to the Department of Veterans Affairs (VA) for the treatment of a veteran patient. The contract was awarded to Bristol-Myers Squibb Company, a large pharmaceutical manufacturer, and has a ceiling value of $335,042.65. The contract is a firm fixed price delivery order under Bristol-Myers Squibb's existing Federal Supply Schedule contract (ID: 36F79724D0101) with the VA, which covers a broad range of drugs, pharmaceuticals, and hematology-related products. This contract does not have a set-aside designation. The work will be primarily performed at Bristol-Myers Squibb's facility in Lawrenceville, New Jersey. The contract supports the VA's mission of providing advanced medical care, including specialized oncology and immunotherapy treatments, to eligible veterans.
Bristol-Myers Squibb Company
$335.0k 2/24/25 3/2/25 2/20/25 Delivery Order 36F79724D0101-36C24924N0625
This is a federal contract award to Bristol-Myers Squibb Company, doing business as Bristol-Myers Squibb, for the delivery of the ABECMA chimeric antigen receptor (CAR) T cell immunotherapy. The award, valued at $314,322.29, is a delivery order placed against Bristol-Myers Squibb's existing Federal Supply Schedule (FSS) contract with the Department of Veterans Affairs Veterans Health Administration (VA VHA). This multiple award FSS contract has a ceiling value of $12,278,876,570.00 and runs through April 30, 2029. The work under this delivery order will be performed in Lawrenceville, New Jersey, and the performance period is expected to be completed by September 26, 2024. This contract award does not carry any set-aside designation, reflecting Bristol-Myers Squibb's status as a large pharmaceutical company. The VA VHA, specifically the Veterans Integrated Service Network 9 (VISN 9), is the funding agency for this delivery order, indicating the widespread use of Bristol-Myers Squibb's advanced oncology treatments across the VA healthcare network.
Bristol-Myers Squibb Company
$0 8/22/24 9/26/24 2/13/25 Delivery Order 36F79724D0101-36C24925N0271
This federal contract award to Bristol-Myers Squibb Company, a global biopharmaceutical company, is for the delivery of two chimeric antigen receptor (CAR) T cell therapies: BREYANZI and ABECMA. The therapies are being supplied to the U.S. Department of Veterans Affairs (VA) and its healthcare system, specifically to various Veterans Integrated Service Networks (VISNs).
The contract, which has a firm fixed price of $314,322.29 and a completion date of February 12, 2025, is a delivery order under Bristol-Myers Squibb's larger Federal Supply Schedule (FSS) contract with the VA. The FSS contract, valued at $12,278,876,570.00, allows the VA to efficiently procure a wide range of drugs, pharmaceuticals, and hematology-related products from the company. This contract award does not carry any set-aside designation, reflecting Bristol-Myers Squibb's status as a large pharmaceutical manufacturer. The work is primarily performed at the company's facility in Lawrenceville, New Jersey.
Bristol-Myers Squibb Company
$314.3k 12/13/24 2/12/25 12/12/24 Delivery Order 36F79724D0101-36C24924F0211
This federal contract award was issued by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 9 (VISN 9) to Bristol-Myers Squibb Company, a global biopharmaceutical company, for the delivery of BREYANZI, a chimeric antigen receptor (CAR) T-cell therapy used to treat non-Hodgkin lymphoma. The $310,953.67 firm fixed-price delivery order has an ultimate completion date of August 30, 2024.
This award is a call against Bristol-Myers Squibb's existing Federal Supply Schedule (FSS) contract (ID: 36F79724D0101) with the VA, which has a ceiling value of $12,278,876,570.00 and runs through April 30, 2029. Under this FSS contract, Bristol-Myers Squibb provides a range of drugs, pharmaceuticals, and hematology-related products to the VA healthcare system. The contract does not carry a set-aside designation, as Bristol-Myers Squibb is a large pharmaceutical manufacturer. This delivery order reflects the VA's continued use of Bristol-Myers Squibb's advanced oncology therapies to support the healthcare needs of veterans.
Bristol-Myers Squibb Company
$311.0k 8/20/24 8/30/24 8/20/24 Delivery Order 36F79724D0101-36C24925F0052
This federal contract award, valued at $314,322.29, is a delivery order issued by the U.S. Department of Veterans Affairs (VA) to Bristol-Myers Squibb Company, a global biopharmaceutical firm. The contract is for the supply of IDECABTAGENE VICLEUCEL/ABECMA INJECTION, a chimeric antigen receptor (CAR) T-cell therapy used to treat certain types of cancer.
The award is not designated as a set-aside contract. It is part of a larger Federal Supply Schedule (FSS) contract (ID: 36F79724D0101) between Bristol-Myers Squibb and the VA, with a total ceiling value of $12,278,876,570.00 and a term running through April 30, 2029. Through this FSS vehicle, Bristol-Myers Squibb provides a range of drugs, pharmaceuticals, and hematology-related products to the VA healthcare system, including its innovative CAR T-cell therapies.
The work under this delivery order will be primarily performed at Bristol-Myers Squibb's facility in Lawrenceville, New Jersey. The contract has a firm fixed price pricing type and an ultimate completion date of November 30, 2024.
Bristol-Myers Squibb Company
$314.3k 10/18/24 11/30/24 10/18/24